• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hong Kong Pharmaceuticals and Healthcare Report Q1 2011 - Product Image

Hong Kong Pharmaceuticals and Healthcare Report Q1 2011

  • Published: November 2010
  • Region: Hong Kong
  • 86 Pages
  • Business Monitor International

FEATURED COMPANIES

  • CK Life Sciences
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Hong Kong Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Hong Kong's pharmaceuticals and healthcare industry.

Growth of the pharmaceutical market in Hong Kong is expected to be steady over the medium term. The market should reach HKD10.56bn (US$1.35bn) in value at consumer prices by 2014, up from the calculated HKD7.19bn (US$926mn) in 2009. This represents a compound annual growth rate (CAGR) of 7.99% in local currency terms, which will somewhat decrease to 7.06% over our longer, ten-year forecast period to 2019. A testament to its attractiveness, Hong Kong now occupies fifth place in the Asia Pacific Pharmaceuticals & Healthcare Business Environment Ratings (BER) matrix for Q111, which ranks 17 key regional markets.

The above forecasts are based on a number of trends and expectations. Private per-capita drug expenditure will continue to rise as the government aims to cut public sector deficits and as expected changes facilitate the creation of private pharmacies in hospitals. READ MORE >

Executive Summary

SWOT Analysis
Hong Kong Pharmaceuticals And Healthcare Industry SWOT
Hong Kong Political SWOT
Hong Kong Economic SWOT
Hong Kong Business Environment SWOT

Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q111
Rewards
Risks

Hong Kong – Market Summary
Regulatory Regime
Recent Regulatory Developments
Chronology Of Drug Incidents In Hong Kong Since March 2009
Intellectual Property Issues
Counterfeit Drugs
Pricing and Reimbursement Regime
Public Procurement of Medicines

Industry Trends and Developments
Epidemiology
Table: Leading Causes Of Death In Hong Kong, 2001-2008
Non-Communicable Diseases
Mental Health
Communicable Diseases
Healthcare Sector
Healthcare Sector Reforms
Healthcare Financing
Recent Developments in Healthcare Financing
Healthcare Insurance
Biotechnology
Clinical Trials
Medical Devices
Table: Examples Of Medical Devices in Hong Kong

Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2006-2014
Key Growth Factors – Industry
Table: Health Expenditure Indicators 2006-2014
Table: Government Health Expenditure Indicators 2006-2014
Table: Private Health Expenditure Indicators 2006-2014
Key Growth Factors – Macroeconomic
Table: Hong Kong – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2006-2014
Patented Drug Market Forecast
Table: Patented Drug Sales Indicators 2006-2014
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2006-2014
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2006-2014
Medical Devices Market Forecast
Table: Medical Device Sales Indicators 2006-2014
Pharmaceutical Trade Forecast
Table: Pharmaceutical Imports & Exports Indicators 2006-2014
Other Healthcare Indicators
Key Risks to BMI’s Forecast Scenario

Competitive Landscape
Pharmaceutical Industry
Traditional Chinese Medicines
Leading Pharmaceutical Companies According To Asia Q210 Sales (US$mn)
Table: Hong Kong's Pharmaceutical Industry
Recent Industry Developments
Pharmaceutical Supply Chain
Retail Pharmacy Sector

Company Profiles
Indigenous Companies
Wuyi International Pharmaceutical
CK Life Sciences
South Asia Pharmamedic
C&Y Pharmaceutical Investment
Vida Laboratories
Multinationals
GlaxoSmithKline
Pfizer
Sanofi-Aventis
Merck & Co
Novartis

Country Snapshot: Hong Kong Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2005-2012

BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

- Wuyi International Pharmaceutical
- CK Life Sciences
- South Asia Pharmamedic
- C&Y Pharmaceutical Investment
- Vida Laboratories
- GlaxoSmithKline
- Pfizer
- Sanofi-Aventis
- Merck & Co
- Novartis

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos